Carcinoma of the intact uterine cervix treated with radiotherapy alone: A french cooperative study: Update and multivariate analysis of prognostics factors

Barillot, I.; Horiot, J.C.; Pigneux, J; Schraub, S; Pourquier, H; Daly, N; Bolla, M.; Rozan, R

doi:10.1016/s0360-3016(97)00145-4

Cited by 146 publications

(70 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reported survival of patients with stage III cervical cancer treated with radiation therapy alone is between 30 and 50% (Barillot et al, 1997). Perez et al (1999) reported 1456 patients given EBRT (whole pelvis and central shielding, total 50 -60 Gy, depending on tumour size) and ICBT (80 -90 Gy at point A for stage IIb -IV disease).…”

Section: Discussionmentioning

confidence: 99%

“…The overall survival was 32%. Barillot et al (1997) reported a large multi-centre study of 1875 patients treated with radiation alone. Specific survival at 5 years was 70% for stage IIb, 55% for stage IIIa, 45% for stage IIIb, and 10% for stage IV disease.…”

Section: Discussionmentioning

confidence: 99%

“…Despite worldwide efforts at screening with the aim of detecting cervical cancer in the early stage, many cancers are not discovered until already advanced. Traditionally, radical hysterectomy or radiation therapy alone has been accepted as standard treatment for early-stage invasive cervical cancer, and locally advanced cancer has been treated by radiotherapy alone consisting of a combination of high-dose-rate intracavitary brachytherapy (ICBT) and external beam radiotherapy (EBRT) (Coia et al, 1990;Komaki et al, 1995;Barillot et al, 1997). In the past few years, substantial advances in the management of locally advanced cervical cancer have been reported.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers

et al. 2007

View full text Add to dashboard Cite

The objective of this retrospective study was to determine the survival rate, incidence of late complications, and incidence of second cancers when radiation therapy alone is used for carcinoma of the uterine cervix. Between 1971 and 1995, 1495 patients with squamous cell carcinoma of the uterine cervix (stages I -IV) were treated with radiation therapy alone in our hospital. Radiation therapy consisted of a combination of high-dose-rate intracavitary brachytherapy and external beam radiotherapy. The cumulative 5-year survival rates for stages Ib, II, and III/IVa carcinoma were 93.5, 77.0, and 60.3%, respectively, and the 10-year survival rates were 90.9, 74.5, and 56.1%, respectively. Local control rates for stages Ib, II, and III/IVa carcinoma were 92.0, 79.4 and 64.2%, respectively. Eighty-two (5.5%) patients suffered grade III/IV or V (fatal) complications. A second cancer developed in 13 (0.87%) patients. Second cancers were observed most frequently in the rectum (five cases), colon (three cases), and uterine body (two cases). Long-term follow-up data revealed that our method of radiation therapy alone for locally advanced carcinoma of the uterine cervix is effective, with low incidences of late complications and second cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Cervical cancer treatment depends on FIGO tumor stages and includes surgery, chemo-, radio-or chemoradiotherapy. For more than 50 years, radiation therapy was the standard treatment for patients with locally advanced cervical carcinoma but patients with advanced stage >IIB disease were cured only in 35-45% of cases with radiation therapy alone (2)(3)(4). According to the European clinical guidelines since 1999 locally advanced cervical carcinomas (FIGO>IIB) are treated with simultaneous cisplatin-based chemoradiotherapy (CCRT) (5).…”

Section: Introductionmentioning

confidence: 99%

Oncostatin M treatment increases the responsiveness toward cisplatin‑based chemoradiotherapy in cervical cancer cells in a STAT3‑dependent manner

et al. 2018

View full text Add to dashboard Cite

Abstract. Cervical cancer stage-dependent therapies include surgery, chemotherapy, radiotherapy and chemoradiotherapy. Concurrent cisplatin-based chemoradiotherapy (CCRT) is the standard therapy for locally advanced cervical carcinoma (FIGO>IIB), however therapy resistance in a subset of patients is still a major clinical challenge. The present study aimed to analyze the impact of Oncostatin M (OSM) stimulation on CCRT-induced cell death. The present study used cells derived from cervical squamous cell carcinomas (SW756, 808, CaSki and 879) and adenocarcinoma (HeLa). The cervical carcinoma cells were HPV18-positive (HeLa, SW756, 808) or HPV16-positive (CaSki, 879). In addition to the established cell lines HeLa, SW756 and CaSki, the more recently generated cervical cancer cells 808 and 879 were also used. To analyze their radiosensitivity, cells were treated with increasing doses of irradiation (0-8 Gy). To mimic chemotherapy, radiotherapy or CCRT in vitro, the cells were challenged with 0.975 µg/ml cisplatin, irradiated with 6 Gy or a combination. A total of 10 ng/ml OSM was applied for 2 h prior to the respective therapy. The responsiveness toward radiation alone varied among the cervical carcinoma cells. CaSki, 808 and 879 cells were resistant to irradiation up to 8 Gy. OSM pre-treatment sensitized two out of five cell lines (HeLa and 879) to irradiation. Notably, all tested cells were sensitized by OSM for CCRT-treatment, particularly in the less radiosensitive cells. Cell death enhancement was dependent on phosphorylated signal transducer and activator of transcription 3 (STAT3; Tyr705) signaling activation as demonstrated with a dominant-negative version of STAT3 interfering with phosphorylation at Tyr705 (dnSTAT3-Y705F). In conclusion, OSM pre-treatment was able to override resistance to CCRT via the STAT3 signaling pathway.

show abstract

“…The combination of external beam radiotherapy (EBRT) and intracavitary brachytherapy (ICBT) is considered the standard of care, except in younger patients with early-stage disease. Many large series have reported 5-year disease-free survival (DFS) rates of 80 -90% for Stage I, 55-70% for Stage II, 30 -50% for Stage III, and 10 -15% for Stage IV disease (5)(6)(7)(8)(9)(10)(11)(12). Conventional ICBT with tandem and ovoids or ovoids alone may not deliver an adequate dose in cases of extensive and bulky tumors, obliterated fornices, lower vaginal involvement, and carcinoma of the cervical stump (13,14).…”

Section: Introductionmentioning

confidence: 99%

Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix

Syed

Puthawala

Abdelaziz

et al. 2002

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Carcinoma of the intact uterine cervix treated with radiotherapy alone: A french cooperative study: Update and multivariate analysis of prognostics factors

Cited by 146 publications

References 27 publications

Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers

Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term survival, late complications, and incidence of second cancers

Oncostatin M treatment increases the responsiveness toward cisplatin‑based chemoradiotherapy in cervical cancer cells in a STAT3‑dependent manner

Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix

Contact Info

Product

Resources

About